Evidence map›Paper›PMID 37046719›Full record

ReviewCancers2023

Patient Derived Organoids (PDOs), Extracellular Matrix (ECM), Tumor Microenvironment (TME) and Drug Screening: State of the Art and Clinical Implications of Ovarian Cancer Organoids in the Era of Precision Medicine.

Giulia Spagnol, Francesca Sensi, Orazio De Tommasi, Matteo Marchetti, Giulio Bonaldo, Livia Xhindoli, Marco Noventa, Marco Agostini, Roberto Tozzi, Carlo Saccardi

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
6.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Oncology research · 2026
    Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Giulia SpagnolDepartment of Women and Children's Health, Clinic of Gynecology and Obstetrics, University of Padua, 35100 Padua, Italy.ORCID 0000-0003-3525-0571
Francesca SensiDepartment of Women and Children's Health, University of Padua, 35100 Padua, Italy.ORCID 0000-0002-9761-824X
Orazio De TommasiDepartment of Women and Children's Health, Clinic of Gynecology and Obstetrics, University of Padua, 35100 Padua, Italy.
Matteo MarchettiDepartment of Women and Children's Health, Clinic of Gynecology and Obstetrics, University of Padua, 35100 Padua, Italy.
Giulio BonaldoDepartment of Women and Children's Health, Clinic of Gynecology and Obstetrics, University of Padua, 35100 Padua, Italy.ORCID 0000-0002-9567-1629
Livia XhindoliDepartment of Women and Children's Health, Clinic of Gynecology and Obstetrics, University of Padua, 35100 Padua, Italy.
Marco NoventaDepartment of Women and Children's Health, Clinic of Gynecology and Obstetrics, University of Padua, 35100 Padua, Italy.
Marco AgostiniFondazione Istituto di Ricerca Pediatrica Città della Speranza, 35129 Padua, Italy.ORCID 0000-0001-7578-1233
Roberto TozziDepartment of Women and Children's Health, Clinic of Gynecology and Obstetrics, University of Padua, 35100 Padua, Italy.ORCID 0000-0001-6123-1628
Carlo SaccardiDepartment of Women and Children's Health, Clinic of Gynecology and Obstetrics, University of Padua, 35100 Padua, Italy.
University of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer (OC) has the highest mortality rate of all gynecological malignancies due to the high prevalence of advanced stages of diagnosis and the high rate of recurrence. Furthermore, the heterogeneity of OC tumors contributes to the rapid development of resistance to conventional chemotherapy. In recent years, in order to overcome these problems, targeted therapies have been introduced in various types of tumors, including gynecological cancer. However, the lack of predictive biomarkers showing different clinical benefits limits the effectiveness of these therapies. This requires the development of preclinical models that can replicate the histological and molecular characteristics of OC subtypes. In this scenario, organoids become an important preclinical model for personalized medicine. In fact, patient-derived organoids (PDO) recapture tumor heterogeneity with the possibility of performing drug screening. However, to best reproduce the patient's characteristics, it is necessary to develop a specific extracellular matrix (ECM) and introduce a tumor microenvironment (TME), which both represent an actual object of study to improve drug screening, particularly when used in targeted therapy and immunotherapy to guide therapeutic decisions. In this review, we summarize the current state of the art for the screening of PDOs, ECM, TME, and drugs in the setting of OC, as well as discussing the clinical implications and future perspectives for the research of OC organoids.

Indexed as

drug screeningextracellular matrixorganoidsovarian cancertumor microenvironment

Identifiers

PMID37046719
PMCPMC10093183
OpenAlexW4361279848

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.